21Aug 2023
Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world data

Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world data

A recent study evaluated the real-world impact of semaglutide, an FDA-approved drug for diabetes and weight loss. Data from 3555 patients across ten health systems showed that, on average, patients lost 4.44% of their initial weight after using semaglutide. Notably, those with a history of diabetes mellitus had less weight loss, while individuals with prediabetes and linaclotide use experienced more significant weight loss. This study highlights the drug's effectiveness in real-world settings but suggests that results may differ from clinical trials. Machine learning analysis also identified factors for further research in tailoring weight loss therapy.

  • #endo-diabetology

Like

Save

Share